On May 12, 2025, Tvardi Therapeutics, Inc. dismissed Ernst & Young as its auditor and appointed Deloitte & Touche, effective immediately after filing its quarterly report for Q1 2025. Additionally, the company announced its financial results on May 13, 2025, for the quarter ended March 31, 2025.